✨ Free AI Report
AIM ImmunoTech Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview AIM ImmunoTech Inc.
Research Preview

AIM ImmunoTech Inc.: Business Overview, Financials & Competitive Analysis

AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's flagship asset is Ampligen (rintatolimod), a double-stranded RN...

Analyst-debate audio for AIM ImmunoTech Inc.

AskCyborg analysts argue the bull and bear cases for AIM ImmunoTech Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
AIM ImmunoTech Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
3/ 10Challenged

Cyborg Score thesis

Early-stage immuno-oncology play with compelling pancreatic cancer combination data but uncertain commercialization path and...

Read the full analyst-debate transcript →
Industry Biotechnology / Immuno-Oncology / Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest AIM ImmunoTech Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

AIM ImmunoTech Inc. Overview

Pro stress-test →

AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's flagship asset is Ampligen (rintatolimod), a double-stranded RNA immunomodulator currently in Phase 2 development for pancreatic cancer in combination with AstraZeneca's Imfinzi, with recent mid-year data showing positive therapeutic effects across multiple cancer types.

Strategic Profile

Pro stress-test →

AIM is positioned in the competitive immunotherapy space with a differentiated mechanism targeting TLR3 agonism. The company is advancing combination therapy approaches for oncology while maintaining legacy products like Alferon N Injection, though current revenue generation remains minimal as the company operates in clinical-stage development mode.

Competitive Landscape

Pro stress-test →

AIM competes in crowded immuno-oncology space against companies like Ayala Pharmaceuticals, Immunocore Holdings, and ImmunityBio. Primary differentiation comes from TLR3-targeted mechanism and combination therapy approach, though Ampligen faces typical development-stage competition from better-capitalized players with more advanced pipeline stages.

Industry Context

AIM ImmunoTech Inc. operates in Biotechnology / Immuno-Oncology / Immunotherapy.

Key facts

Headquarters: Ocala, Florida · Revenue: $112K · Market cap: $3.74M

What the analysts stress-tested

The top findings that survived the multi-agent debate for AIM ImmunoTech Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when AIM ImmunoTech Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Immunomodulatory therapeuticsPrecision oncology immunotherapy developer→Immunotherapy platformsCell and gene therapy for cancer and infectious disease→Immune checkpoint approachesT-cell redirected immunotherapy leader→

Compare AIM ImmunoTech Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

AIM ImmunoTech Inc. operates in Biotechnology / Immuno-Oncology / Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Immuno-Oncology / Immunotherapy research →
NEW · MCP server

Ask your AI assistant about AIM ImmunoTech Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare AIM ImmunoTech Inc. and its top competitor on Cyborg Score”
“What did AIM ImmunoTech Inc. do this quarter?”
“Is AIM ImmunoTech Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does AIM ImmunoTech Inc. do?+
AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's flagship asset is Ampligen (rintatolimod), a double-stranded RN...
What is AIM ImmunoTech Inc.'s Cyborg Score?+
AIM ImmunoTech Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are AIM ImmunoTech Inc.'s main competitors?+
Named competitors include Immunomodulatory therapeutics, Immunotherapy platforms, Immune checkpoint approaches. The full competitive landscape is in the AskCyborg report.
How can I get the full AIM ImmunoTech Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the AIM ImmunoTech Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track AIM ImmunoTech Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score